UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549




FORM 8-K

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934








Date of Report: September 30, 2009

(Date of earliest event reported)




ImmuCell Corporation

(Exact name of registrant as specified in its charter)





ME

(State or other jurisdiction 
of incorporation)


001-12934

(Commission File Number)


01-0382980

(IRS Employer 
Identification Number)






56 Evergreen Drive

(Address of principal executive offices)

 

04103

(Zip Code)




207-878-2770
(Registrant's telephone number, including area code)




Not Applicable
(Former Name or Former Address, if changed since last report)








Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  







Item 8.01. Other Events



ImmuCell Announces Initial Results from its pivotal effectiveness study of Mast Out(R).

ImmuCell's Mastitis Drug Meets Pivotal Effectiveness Study End Point.


Item 9.01. Financial Statements and Exhibits






(a) Financial statements:

             None

(b) Pro forma financial information:

             None

(c) Shell company transactions:

             None

(d) Exhibits

             99.1       Press Release of ImmuCell Corporation dated September 30, 2009






SIGNATURE


      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.








Dated: September 30, 2009



IMMUCELL CORPORATION


By:  /s/ Michael F. Brigham                      

     Michael F. Brigham

     President and CEO








Exhibit Index



Exhibit No.
Description


99.1
Press Release of ImmuCell Corporation dated September 30, 2009